Ibex’s Galen™ Prostate solution is now used in routine clinical practice at France’s largest network of pathology labs, helping pathologists improve diagnostic accuracy
Tel Aviv, Israel, and Frejus, France - July 21, 2020 - Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-based cancer diagnostics, and Medipath, the largest network of private pathology labs in France, announced today the first ever deployment of an AI-powered solution for cancer detection in pathology in France.
France, as with most European countries, is challenged by an increasing prevalence of cancer, leading to increased demand for diagnostic testing. This coincides with a global decline in the number of pathologists, the experts required to diagnose disease, resulting in increased workloads. For many labs, the fundamentals of cancer diagnosis have remained unchanged for decades with pathologists looking at biopsies through a microscope. The process is manual and thus prone to human error. Ibex now offers a clinical grade, field proven AI-based solution that helps pathologists meet these challenges.
Medipath, which provides pathology services to more than 170 hospitals and clinics across France, has completed deployment of Ibex’s Galen Prostate as part of its routine clinical practice. With Ibex’s CE-marked solution, a highly accurate AI algorithm analyzes prostate biopsies and raises alerts when discrepancies with the pathologists’ initial diagnosis are identified. Alerts can include a potential missed cancer and provide a safety net that helps minimize diagnostic errors in the lab by enhancing quality control. The Galen Prostate has demonstrated outstanding results in clinical studies, including an unmatched AUC (Area Under Curve) of 0.997 for cancer detection, and has already been successful in detecting missed cancers in real time.
“Medipath’s implementation of Galen Prostate represents a significant step in our global expansion and extends the scope of cooperation between our companies to routine cancer diagnosis - the core of Medipath’s clinical practice,” said Joseph Mossel, CEO and Co-Founder of Ibex. “We are happy to share the vision that AI-powered pathologists will take the center stage in the future, with AI applications becoming standard in the cancer pathway and patient care.”
“This is a watershed moment not only for Medipath, but for pathology and cancer care in France,” said Delphine Raoux, MD, Head of Innovation Technologies at Medipath. “Medipath is committed to exploring new technologies and providing the best service to its customers and ultimately their patients. This is an important step for leveraging our leadership position to support pathologists and assist them in improving diagnostic quality and workflow efficiency. AI can be a tool in the future of pathology, and we are thrilled to be the first lab in France to reach this milestone. We look forward to working with Ibex on transformative solutions for cancer diagnosis.”